Moderna Inc. (MRNA)

14.32
0.12 0.85
NASDAQ : Health Technology
Prev Close 14.20
Open 14.28
Day Low/High 14.00 / 14.46
52 Wk Low/High 13.03 / 29.79
Volume 720.55K
Avg Volume 1.23M
Exchange NASDAQ
Shares Outstanding 329.01M
Market Cap 4.75B
EPS -5.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Newly Published Pre-Clinical Data Show Intratumoral Injections Of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses In Treated And Distal Tumors

Newly Published Pre-Clinical Data Show Intratumoral Injections Of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses In Treated And Distal Tumors

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of pre-clinical data that...

Dr. John Mendlein To Transition To An Advisory Role At Moderna And Join Flagship Pioneering As An Executive Partner

Dr. John Mendlein To Transition To An Advisory Role At Moderna And Join Flagship Pioneering As An Executive Partner

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that John Mendlein, Ph.

Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019

Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019

Moderna only went public in December, and is already creating a buzz.

Moderna Shares Jump on Positive Cancer-Treatment Progress

Moderna Shares Jump on Positive Cancer-Treatment Progress

Report on positive results of new drugs to treat ovarian and other cancers sends shares higher.

Moderna Announces Recent Progress In Its Immuno-Oncology And Rare Disease Programs And Highlights Corporate Objectives

Moderna Announces Recent Progress In Its Immuno-Oncology And Rare Disease Programs And Highlights Corporate Objectives

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced recent updates to several of its...

Moderna To Provide Business And Pipeline Updates At The 2019 J.P. Morgan Healthcare Conference

Moderna To Provide Business And Pipeline Updates At The 2019 J.P. Morgan Healthcare Conference

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced today that CEO Stéphane Bancel will present an...

It's a Two-Sided Market: Cramer's 'Mad Money' Recap (Monday 12/10/18)

It's a Two-Sided Market: Cramer's 'Mad Money' Recap (Monday 12/10/18)

There are two sides, or more, to every market story these days, Jim Cramer says.

Biotech Moderna Slides in Its Trading Debut

Biotech Moderna Slides in Its Trading Debut

Drug developing startup Moderna Inc. raises $604.3 million for an initial public offering running up to its expected Nasdaq debut Friday.

Moderna Announces Pricing Of Initial Public Offering

Moderna Announces Pricing Of Initial Public Offering

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the pricing of its initial public offering...

Marina Biotech And Mirna Therapeutics Amend License Agreement For The Development Of MicroRNA-based Therapeutics

Marina Biotech And Mirna Therapeutics Amend License Agreement For The Development Of MicroRNA-based Therapeutics

Marina Biotech, Inc. (OTC Pink: MRNA), a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc.

5 Biggest Drug-Stock Losers of 2011

5 Biggest Drug-Stock Losers of 2011

Reading this list of stinkers incites a little Schadenfreude as one company fell 99.6%.

Encorium Group, MDRNA: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Monday's session.

7 Firms Developing RNAi Drugs

7 Firms Developing RNAi Drugs

Biotech investors are paying close attention to RNAi. Here are seven drug and biotech companies focused on developing RNAi drugs.

MRNA, Pacific Ethanol: Midday Volume Plays

Several stocks trading near $5 were moving on above-average volume during Monday's session.

Sirius XM, Tellabs: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.

MDRNA Draws Bullish Options Trade

MDRNA, a drug developer, reported positive results for an experimental cancer treatment last week and at least one investor is positioning for a rally by summer.

Ballard Power, Enterra: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.

MDRNA, Affymetrix: Early Volume Plays

MDRNA, Affymetrix: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Wednesday's session.

MDRNA Shares Rise On Debt Repayment

MDRNA Shares Rise On Debt Repayment

MDRNA shares rise following full repayment of $5.5 million in debt to GE Capital

Texas Instruments, Ceradyne Are Big Movers

Texas Instruments, Ceradyne, Quiksilver, Marvell Technology among big market movers Tuesday